ACCRA, Ghana & NEW YORK
(BUSINESS WIRE) -- The West African Monetary Institute (WAMI) and EMTECH SOLUTIONS Inc. today announced a strategic partnership to modernize country-level and regional regulatory sandboxes, enabling the harmonization of heterogeneous Fintech regulatory policies and frameworks across the West African Monetary Zone (WAMZ). The collaboration aims at strengthening financial integration across the WAMZ member states.
WAMI and EMTECH will establish a knowledge and collaboration program called WAMZ RegEX, which focuses on showcasing regulatory innovation, sharing insights from global and regional regulatory sandbox benchmarking, onboarding a cohort of WAMZ regulatory sandboxes to conduct rapid pilots, and promoting value. Additionally, the partnership will involve publishing research and case studies, as well as capacity-building programs and thought-leadership workshops.
Olorunsola E. Olowofeso, Director General of the West African M
...
Read more »
|
PALO ALTO, Calif. - Friday, 26. May 2023
Leading SaaS and B2C companies launch in new regions in weeks, not years.
(BUSINESS WIRE)--Today Skyflow, the data privacy vault company, announced new data residency capabilities including Asia-Pacific instances in Japan, Indonesia, India, and Bahrain, and an expansion of its footprint in EMEA and North America.
With Skyflow, companies that store sensitive customer data can meet regulatory requirements for localized storage, provable and auditable data protection, and governance – simply by leveraging Skyflow’s global vault infrastructure. This enables global expansion to reach new customers in new markets, while minimizing complexity and cost. For example, SaaS ISVs can scale and sell their product in both EMEA and APAC without adding instances.
Replicating Instances is Expensive and Slow
Today, companies that want to expand internationally face a technically complex and e
...
Read more »
|
OSAKA, Japan & CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J. - Friday, 26. May 2023 AETOSWire Print
− Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 30, 2023
− NDA Includes Results From the Phase 3 FRESCO-2 and FRESCO Clinical Trials
(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (HUTCHMED) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC). If approved, fruquintinib will be the first and only highly selective inhibitor of all three VEGF receptors approved in the U.S. for previously treated metastatic CRC.1,2 The Prescription Drug User F
...
Read more »
|
Moscow, Russia - Friday, 26. May 2023 AETOSWire
The Russian capital has just finished hosting the II Moscow Interior and Design Week, which combined several major activities for industry: expo and marketplace, open discussions, lectures and workshops.
For several days, exhibition pavilions in Moscow were transformed into venues where companies and creators from all over the world showcased their creative furniture and interior design solutions, along with modern installations, while the attendees had an opportunity to buy the latest industry novelties at a discount.
This year's event brought together more than 650 Russian and international brands: leaders and trend-setters in the industry. The exhibition program saw contributions from foreign companies representing India, Peru, Turkey, Iran, Vietnam, and other countries. Flagship brands, up-and-coming businesses, and authentic local companies pres
...
Read more »
|
Not intended for UK-, US- or Canada-based media
(BUSINESS WIRE) -- Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US. New data for the medicines BAVENCIO® (avelumab), ERBITUX® (cetuximab), and TEPMETKO® (tepotinib) and pipeline assets including the first-in-class investigational IAP (inhibitor of apoptosis protein) inhibitor xevinapant demonstrate the Company’s efforts to pioneer novel medicines intended to improve the lives of people living with cancer.
“The research we will present at ASCO 2023 demonstrates that we are not only maximizing the impact of our standard-of-care treatments but also advancing development programs focused on synergistic approaches targeting key cancer pathways and mechanisms,” said Victoria Zazulina, M.D., Head of Deve
...
Read more »
|
|